Research programme: HIV fusion inhibitors - Borean Pharma
Latest Information Update: 07 Nov 2007
At a glance
- Originator Borean Pharma
- Mechanism of Action HIV fusion inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical HIV infections
Most Recent Events
- 23 Oct 2007 This programme is still in active development
- 25 Feb 2004 Preclinical trials in HIV infections treatment in Denmark (unspecified route)